Tenet Healthcare price target raised to $105 from $92 at Truist

Truist raised the firm’s price target on Tenet Healthcare to $105 from $92 and keeps a Buy rating on the shares. The analyst cites the company’s strong Q4 results and normalized guidance which calls for attractive adjusted EBITDA growth. Tenet’s ASC trends remain strong, core hospital volumes are solid, and ongoing investments on several fronts including labor and high acuity service lines continue to bear fruit, the firm added.